BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month vs 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-513. [PMID: 22179532 DOI: 10.1161/circulationaha.111.059022] [Cited by in Crossref: 423] [Cited by in F6Publishing: 91] [Article Influence: 42.3] [Reference Citation Analysis]
Number Citing Articles
1 Valgimigli M, Sabaté M, Kaiser C, Brugaletta S, de la Torre Hernandez JM, Galatius S, Cequier A, Eberli F, de Belder A, Serruys PW. Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ. 2014;349:g6427. [PMID: 25378023 DOI: 10.1136/bmj.g6427] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 9.7] [Reference Citation Analysis]
2 Matteau A, Yeh RW, Camenzind E, Steg PG, Wijns W, Mills J, Gershlick A, de Belder M, Ducrocq G, Mauri L. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015;116:686-693. [PMID: 26187674 DOI: 10.1016/j.amjcard.2015.05.036] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
3 Ki YJ, Kang J, Park J, Han JK, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians. J Clin Med 2020;9:E652. [PMID: 32121235 DOI: 10.3390/jcm9030652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 2015;313:1113-21. [PMID: 25781440 DOI: 10.1001/jama.2015.1671] [Cited by in Crossref: 64] [Cited by in F6Publishing: 42] [Article Influence: 10.7] [Reference Citation Analysis]
5 Pfisterer M, Kaiser C, Jeger R. No One-Size-Fits-All: A Tailored Approach to Antithrombotic Therapy After Stent Implantation. Circulation 2012;125:471-3. [DOI: 10.1161/circulationaha.111.078923] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
6 Park TK, Song YB, Ahn J, Carriere KC, Hahn JY, Yang JH, Choi SH, Choi JH, Lee SH, Gwon HC. Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents. Circ Cardiovasc Interv 2016;9:e002816. [PMID: 26755571 DOI: 10.1161/CIRCINTERVENTIONS.115.002816] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
7 Rha SW. Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents. World J Cardiol 2014;6:148-53. [PMID: 24772255 DOI: 10.4330/wjc.v6.i4.148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Li Q, Tong Z, Wang L, Zhang J, Ge Y, Wang H, Li W, Xu L, Ni Z, Yang X. Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. Arch Med Sci 2013;9:1040-8. [PMID: 24482648 DOI: 10.5114/aoms.2013.39793] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Bittl JA, Baber U, Bradley SM, Wijeysundera DN; Evidence Review Committee Members. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016;134. [DOI: 10.1161/cir.0000000000000405] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
10 Jang WJ, Ahn SG, Song YB, Choi S, Chun WJ, Oh JH, Cho SW, Kim BS, Yoon JH, Koo B, Yu CW, Jang YS, Tahk S, Kim H, Gwon H, Lee SY, Hahn J. Benefit of Prolonged Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stent for Coronary Bifurcation Lesions: Results From the Coronary Bifurcation Stenting Registry II. Circ: Cardiovascular Interventions 2018;11. [DOI: 10.1161/circinterventions.117.005849] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, Yeh RW. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015;385:792-8. [PMID: 25467565 DOI: 10.1016/S0140-6736(14)62052-3] [Cited by in Crossref: 122] [Cited by in F6Publishing: 28] [Article Influence: 17.4] [Reference Citation Analysis]
12 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 28] [Article Influence: 81.0] [Reference Citation Analysis]
14 Bundhun PK, Yanamala CM, Huang F. Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies. BMC Cardiovasc Disord 2016;16:161. [PMID: 27577530 DOI: 10.1186/s12872-016-0343-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36:3320-3331. [PMID: 26417060 DOI: 10.1093/eurheartj/ehv511] [Cited by in Crossref: 268] [Cited by in F6Publishing: 147] [Article Influence: 44.7] [Reference Citation Analysis]
16 Kinnaird T, Butt M, Abdul F, Yazji K, Hailan A, Gallagher S, Ossei-Gerning N, Chase A, Choudhury A, Smith D, Anderson R. Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy. PLoS One 2016;11:e0157812. [PMID: 27362841 DOI: 10.1371/journal.pone.0157812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Helft G, Le Feuvre C, Georges JL, Carrie D, Leclercq F, Eltchaninoff H, Furber A, Prunier F, Sebagh L, Cattan S. Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials. 2013;14:56. [PMID: 23433461 DOI: 10.1186/1745-6215-14-56] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
18 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Krackhardt F, Waliszewski M, Rischner J, Piot C, Pansieri M, Ruiz-Poveda FL, Boxberger M, Noutsias M, Ríos XF, Kherad B. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT). Herz 2019;44:433-9. [PMID: 29356832 DOI: 10.1007/s00059-017-4675-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK, Gilard M, Kim HS, Colombo A, Bhatt DL, Kim BK, Morice MC, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [PMID: 27811064 DOI: 10.1136/bmj.i5483] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
21 Flannery L, Liu R, Elmariah S. Dual Antiplatelet Therapy: How Long Is Long Enough? Curr Treat Options Cardiovasc Med 2019;21:17. [PMID: 30929096 DOI: 10.1007/s11936-019-0721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Reddy K, Khaliq A, Henning RJ. Recent advances in the diagnosis and treatment of acute myocardial infarction. World J Cardiol 2015;7:243-76. [PMID: 26015857 DOI: 10.4330/wjc.v7.i5.243] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
23 Khan SU, Shahzeb Khan M, Kaluski E, Alkhouli MA. Compliance with the prescription of recommended medical therapy in trials comparing six versus 12 months or longer dual antiplatelet therapy: A systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:1673-6. [PMID: 30727767 DOI: 10.1177/2047487319829947] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Galper BZ, Mauri L. Antiplatelet therapy after coronary stenting. Curr Treat Options Cardiovasc Med 2013;15:1-10. [PMID: 23263881 DOI: 10.1007/s11936-012-0223-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
25 Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Igarashi K, Tanabe K, Kozuma K, Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther 2016;31:196-209. [PMID: 26518420 DOI: 10.1007/s12928-015-0366-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
26 Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart 2015;101:1569-76. [PMID: 26209334 DOI: 10.1136/heartjnl-2014-307168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
27 Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther 2018;8:630-46. [PMID: 30498687 DOI: 10.21037/cdt.2018.10.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
28 Lohaus R, Michel J, Mayer K, Lahmann AL, Byrne RA, Wolk A, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Wöhrle J, Kufner S, Morath T, Ibrahim T, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A, Schulz-Schüpke S. Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. Sci Rep 2016;6:33054. [PMID: 27624287 DOI: 10.1038/srep33054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
29 Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J 2015;169:222-233.e5. [PMID: 25641531 DOI: 10.1016/j.ahj.2014.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
30 Capodanno D, Angiolillo DJ. Management of Antiplatelet Therapy in Patients With Coronary Artery Disease Requiring Cardiac and Noncardiac Surgery. Circulation 2013;128:2785-98. [DOI: 10.1161/circulationaha.113.003675] [Cited by in Crossref: 61] [Cited by in F6Publishing: 12] [Article Influence: 7.6] [Reference Citation Analysis]
31 Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019;365:l2222. [PMID: 31253632 DOI: 10.1136/bmj.l2222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 20.5] [Reference Citation Analysis]
32 Habib A, Karmali V, Polavarapu R, Akahori H, Pachura K, Finn AV. Metformin impairs endothelialization after placement of newer generation drug eluting stents. Atherosclerosis 2013;229:385-7. [PMID: 23880192 DOI: 10.1016/j.atherosclerosis.2013.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
33 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
35 Collet JP, Silvain J, Kerneis M, Cuisset T, Meneveau N, Boueri Z, Barthélémy O, Rangé G, Cayla G, Belle EV, Elhadad S, Carrié D, Caussin C, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; ARCTIC Investigators. Clinical Outcome of First- vs Second-Generation DES According to DAPT Duration: Results of ARCTIC-Generation. Clin Cardiol 2016;39:192-200. [PMID: 26880570 DOI: 10.1002/clc.22512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
36 Bittl JA, He Y. Bayesian Analysis: A Practical Approach to Interpret Clinical Trials and Create Clinical Practice Guidelines. Circ Cardiovasc Qual Outcomes 2017;10:e003563. [PMID: 28798016 DOI: 10.1161/CIRCOUTCOMES.117.003563] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
37 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 69] [Article Influence: 128.0] [Reference Citation Analysis]
38 Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, Gilard M, Morice MC, Valgimigli M, Hong MK, Kim BK, Jang Y, Kim HS, Park KW, Colombo A, Chieffo A, Sangiorgi D, Biondi-Zoccai G, Généreux P, Angelini GD, Pufulete M, White J, Bhatt DL, Stone GW. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J 2017;38:1034-43. [PMID: 28110296 DOI: 10.1093/eurheartj/ehw627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
39 Degrauwe S, Pilgrim T, Aminian A, Noble S, Meier P, Iglesias JF. Dual antiplatelet therapy for secondary prevention of coronary artery disease. Open Heart 2017;4:e000651. [PMID: 29081979 DOI: 10.1136/openhrt-2017-000651] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
40 Murase S, Suzuki Y, Yamaguchi T, Matsuda O, Murata A, Ito T. The relationship between re-endothelialization and endothelial function after DES implantation: comparison between paclitaxcel eluting stent and zotarolims eluting stent. Catheter Cardiovasc Interv 2014;83:412-7. [PMID: 23901005 DOI: 10.1002/ccd.25140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
41 Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ 2016;352:i493. [PMID: 26858277 DOI: 10.1136/bmj.i493] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 15.6] [Reference Citation Analysis]
42 Pellegrini DO, Gomes VO, Lasevitch R, Smidt L, Azeredo MA, Ledur P, Bodanese R, Sinnott L, Moriguchi E, Caramori P. Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol 2014;103:174-82. [PMID: 25098375 DOI: 10.5935/abc.20140110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Watanabe H, Morimoto T, Natsuaki M, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Miki S, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kastrati A, Kimura T; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Antiplatelet therapy discontinuation and the risk of serious cardiovascular events after coronary stenting: observations from the CREDO-Kyoto Registry Cohort-2. PLoS One 2015;10:e0124314. [PMID: 25853836 DOI: 10.1371/journal.pone.0124314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheter Cardiovasc Interv 2017;89:1176-84. [PMID: 27860195 DOI: 10.1002/ccd.26831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
45 Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M, Parati G, Lip GY, Kelm M, Valgimigli M. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. [PMID: 25883067 DOI: 10.1136/bmj.h1618] [Cited by in Crossref: 216] [Cited by in F6Publishing: 130] [Article Influence: 36.0] [Reference Citation Analysis]
46 Yeh RW, Mauri L, Kereiakes DJ. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol 2015;65:787-90. [PMID: 25720621 DOI: 10.1016/j.jacc.2015.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 Thukkani AK, Agrawal K, Prince L, Smoot KJ, Dufour AB, Cho K, Gagnon DR, Sokolovskaya G, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. J Am Coll Cardiol 2015;66:1091-101. [PMID: 26337986 DOI: 10.1016/j.jacc.2015.06.1339] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
48 Thim T, Johansen MB, Chisholm GE, Schmidt M, Kaltoft A, Sørensen HT, Thuesen L, Kristensen SD, Bøtker HE, Krusell LR, Lassen JF, Thayssen P, Jensen LO, Tilsted HH, Maeng M. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014;14:100. [PMID: 25125079 DOI: 10.1186/1471-2261-14-100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
49 Xu Y, Shen Y, Chen D, Zhao P, Jiang J. Efficacy and Safety of Dual Antiplatelet Therapy in Patients Undergoing Coronary Stent Implantation: A Systematic Review and Network Meta-Analysis. J Interv Cardiol 2021;2021:9934535. [PMID: 34035674 DOI: 10.1155/2021/9934535] [Reference Citation Analysis]
50 Sousa-Uva M, Storey R, Huber K, Falk V, Leite-Moreira AF, Amour J, Al-Attar N, Ascione R, Taggart D, Collet JP; ESC Working Group on Cardiovascular Surgery and ESC Working Group on Thrombosis. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J 2014;35:1510-4. [PMID: 24748565 DOI: 10.1093/eurheartj/ehu158] [Cited by in Crossref: 53] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
51 Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M, Tummala K, Katagiri Y, Asano T, Tenekecioglu E, Zeng Y, Cavalcante R, Collet C, Onuma Y, Serruys PW. Single or dual antiplatelet therapy after PCI. Nat Rev Cardiol 2017;14:294-303. [PMID: 28181585 DOI: 10.1038/nrcardio.2017.12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
52 Tsoi MF, Cheung CL, Cheung TT, Wong IC, Kumana CR, Tse HF, Cheung BM. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. Sci Rep 2015;5:13204. [PMID: 26278959 DOI: 10.1038/srep13204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
53 Généreux P, Rutledge DR, Palmerini T, Caixeta A, Kedhi E, Hermiller JB, Wang J, Krucoff MW, Jones-McMeans J, Sudhir K. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus- Eluting Stents: Insights From the Xience V Coronary Stent System Trials. Circ Cardiovasc Interv. 2015;8:e001362. [PMID: 25940520 DOI: 10.1161/circinterventions.114.001362] [Cited by in Crossref: 42] [Cited by in F6Publishing: 7] [Article Influence: 8.4] [Reference Citation Analysis]
54 Kang J, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". Korean Circ J 2018;48:537-51. [PMID: 29968428 DOI: 10.4070/kcj.2018.0166] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 7.7] [Reference Citation Analysis]
55 Yang J, Fan ZX, Yang CJ, Wang HB. A Meta-Analysis of Randomized Clinical Trials Comparing Shorter (Less or Equal Than 6 Months) and Longer (More or Equal Than 12 Months) Dual Anti-Platelet Therapy Following Drug-Eluting Coronary Stents. Iran Red Crescent Med J 2015;17:e26904. [PMID: 26421177 DOI: 10.5812/ircmj.26904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Matteau A, Bhatt DL. Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ 2014;186:589-96. [PMID: 24190992 DOI: 10.1503/cmaj.130506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Liu C, Liu M, Chen D, Liu H, Jiang Q, Lu J, Zuo L. Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis. Herz 2015;40:795-802. [PMID: 25911050 DOI: 10.1007/s00059-015-4304-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Gouya G, Arrich J, Wolzt M, Huber K, Verheugt FW, Gurbel PA, Pirker-kees A, Siller-matula JM. Antiplatelet Treatment for Prevention of Cerebrovascular Events in Patients With Vascular Diseases: A Systematic Review and Meta-Analysis. Stroke 2014;45:492-503. [DOI: 10.1161/strokeaha.113.002590] [Cited by in Crossref: 48] [Cited by in F6Publishing: 19] [Article Influence: 6.9] [Reference Citation Analysis]
59 Chang M, Park DW. Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer? Cardiol Ther 2014;3:1-12. [PMID: 25367504 DOI: 10.1007/s40119-014-0030-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
60 Lee CW, Ahn J, Park D, Kang S, Lee S, Kim Y, Park S, Han S, Lee S, Seong I, Rha S, Jeong M, Lim D, Yoon J, Hur S, Choi Y, Yang J, Lee N, Kim H, Lee B, Kim K, Lee S, Chae J, Cheong S, Suh I, Park H, Nah D, Jeon D, Seung K, Lee K, Jang J, Park S. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial. Circulation 2014;129:304-12. [DOI: 10.1161/circulationaha.113.003303] [Cited by in Crossref: 195] [Cited by in F6Publishing: 47] [Article Influence: 27.9] [Reference Citation Analysis]
61 Cho MS, Park DW. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. Korean J Intern Med 2017;32:769-79. [PMID: 28823143 DOI: 10.3904/kjim.2016.391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
62 Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open 2019;9:e033774. [PMID: 31852711 DOI: 10.1136/bmjopen-2019-033774] [Reference Citation Analysis]
63 Mischke K, Knackstedt C, Marx N. Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. Thrombosis 2012;2012:184573. [PMID: 22577538 DOI: 10.1155/2012/184573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
64 Brener SJ. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? All patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy. Circulation. 2015;131:2001-2009; discussion 2009. [PMID: 26034082 DOI: 10.1161/circulationaha.114.013279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA 2019;321:2428-37. [PMID: 31237645 DOI: 10.1001/jama.2019.8146] [Cited by in Crossref: 202] [Cited by in F6Publishing: 128] [Article Influence: 101.0] [Reference Citation Analysis]
66 Garratt KN, Weaver WD, Jenkins RG, Pow TK, Mauri L, Kereiakes DJ, Winters KJ, Christen T, Allocco DJ, Lee DP. Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement. Circulation 2015;131:62-73. [DOI: 10.1161/circulationaha.114.013570] [Cited by in Crossref: 46] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
67 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
68 Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’gara PT, Sabatine MS, Smith PK, Smith SC. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 2016;134. [DOI: 10.1161/cir.0000000000000404] [Cited by in Crossref: 551] [Cited by in F6Publishing: 174] [Article Influence: 110.2] [Reference Citation Analysis]
69 Kim CH, Han JK, Yang HM, Park KW, Lee HY, Kang HJ, Koo BK, Lee N, Cha TJ, Yang TH, Jeong MH, Yoon MH, Lee SU, Lee SJ, Kim JW, Cho JM, Han KR, Pyun WB, Kim HS. Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis - coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial. BMJ Open 2017;7:e016617. [PMID: 29025834 DOI: 10.1136/bmjopen-2017-016617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Kim HS, Valgimigli M, Colombo A, Gilard M, Palmerini T, Stone GW. Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circ Cardiovasc Interv 2016;9:e004256. [PMID: 27803041 DOI: 10.1161/CIRCINTERVENTIONS.116.004256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
71 Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, Li X, Zhao X, Wang H, Zhao X, Li X, Yu P, Zang H, Wang Z, Cao X, Zhang J, Pang W, Li J, Yang Y, Dangas GD. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial. Circ: Cardiovascular Interventions 2016;9. [DOI: 10.1161/circinterventions.115.003145] [Cited by in Crossref: 79] [Cited by in F6Publishing: 28] [Article Influence: 15.8] [Reference Citation Analysis]
72 Villablanca PA, Massera D, Mathew V, Bangalore S, Christia P, Perez I, Wan N, Schulz-Schüpke S, Briceno DF, Bortnick AE, Garcia MJ, Lucariello R, Menegus M, Pyo R, Wiley J, Ramakrishna H. Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression. Medicine (Baltimore) 2016;95:e5819. [PMID: 28033306 DOI: 10.1097/MD.0000000000005819] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
73 Ariotti S, Gargiulo G, Valgimigli M. Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. Curr Cardiol Rep. 2017;19:2. [PMID: 28097533 DOI: 10.1007/s11886-017-0810-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart 2017;103:573-80. [PMID: 28249994 DOI: 10.1136/heartjnl-2016-309871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
75 Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev 2017;12:CD005158. [PMID: 29240976 DOI: 10.1002/14651858.CD005158.pub4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
76 Abraham NS, Hartman C, Richardson P, Castillo D, Street RL Jr, Naik AD. Risk of lower and upper gastrointestinal bleeding, transfusions, and hospitalizations with complex antithrombotic therapy in elderly patients. Circulation. 2013;128:1869-1877. [PMID: 24025594 DOI: 10.1161/circulationaha.113.004747] [Cited by in Crossref: 70] [Cited by in F6Publishing: 20] [Article Influence: 8.8] [Reference Citation Analysis]
77 Li H, Guo W, Dai W, Li L. Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:1815-25. [PMID: 29970956 DOI: 10.2147/DDDT.S165435] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Gillette M, Morneau K, Hoang V, Virani S, Jneid H. Antiplatelet Management for Coronary Heart Disease: Advances and Challenges. Curr Atheroscler Rep 2016;18:35. [PMID: 27139709 DOI: 10.1007/s11883-016-0581-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
79 Misumida N, Abo-Aly M, Kim SM, Ogunbayo GO, Abdel-Latif A, Ziada KM. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clin Cardiol 2018;41:1455-62. [PMID: 30225978 DOI: 10.1002/clc.23075] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
80 Meredith IT, Tanguay J, Kereiakes DJ, Cutlip DE, Yeh RW, Garratt KN, Lee DP, Steg PG, Weaver WD, Holmes DR, Brindis RG, Trebacz J, Massaro JM, Hsieh W, Mauri L. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation 2016;133:1772-82. [DOI: 10.1161/circulationaha.115.016783] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
81 Schurtz G, Delhaye C, Hurt C, Thieuleux H, Lemesle G. Biodegradable polymer Biolimus-eluting stent (Nobori®) for the treatment of coronary artery lesions: review of concept and clinical results. Med Devices (Auckl) 2014;7:35-43. [PMID: 24600254 DOI: 10.2147/MDER.S44051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
82 Ziada KM, Abdel-Latif AK, Charnigo R, Moliterno DJ. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv 2016;87:722-32. [PMID: 26309050 DOI: 10.1002/ccd.26110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
83 Rozemeijer R, Voskuil M, Greving JP, Bots ML, Doevendans PA, Stella PR. Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. Neth Heart J 2018;26:242-51. [PMID: 29541996 DOI: 10.1007/s12471-018-1104-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Han YL. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132:197-210. [PMID: 30614864 DOI: 10.1097/CM9.0000000000000047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
85 Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9:439-453. [PMID: 22614618 DOI: 10.1038/nrcardio.2012.64] [Cited by in Crossref: 222] [Cited by in F6Publishing: 160] [Article Influence: 24.7] [Reference Citation Analysis]
86 Nef H, Renker M, Hamm CW; European Society of Cardiology; European Association for Cardio-thoracic Surgery. [ESC/EACTS guidelines on myocardial revascularization: Amendments 2014]. Herz. 2014;39:913-918. [PMID: 25406330 DOI: 10.1007/s00059-014-4180-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
87 Gajulapalli RD, Dias S, Pattanshetty DJ, Athappan G. Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. Anatol J Cardiol 2017;18:251-60. [PMID: 29076813 DOI: 10.14744/AnatolJCardiol.2017.7672] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Becker RC, Helmy T. Are at least 12 months of dual antiplatelet therapy needed for all patients with drug-eluting stents? Not all patients with drug-eluting stents need at least 12 months of dual antiplatelet therapy. Circulation. 2015;131:2010-2019; discussion 2019. [PMID: 26034083 DOI: 10.1161/circulationaha.114.013281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
89 Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ., Faculty for approval of the Consensus Document . Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl 2018;20:F1-F74. [PMID: 29867293 DOI: 10.1093/eurheartj/suy019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
90 Habib A, Finn AV. Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res 2015;93:22-7. [PMID: 25533811 DOI: 10.1016/j.phrs.2014.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
91 Tada T, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Byrne RA, Kastrati A, Kadota K, Iwabuchi M, Shizuta S, Tazaki J, Shiomi H, Abe M, Ehara N, Mizoguchi T, Mitsuoka H, Inada T, Araki M, Kaburagi S, Taniguchi R, Eizawa H, Nakano A, Suwa S, Takizawa A, Nohara R, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T. Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation: Landmark Analyses From the CREDO-Kyoto PCI/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012;5:381-91. [DOI: 10.1161/circinterventions.111.967463] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]